DOES AUTO TRANSFUSION OF UNPROCESSED RESIDUAL BLOOD IN THE CARDIOPULMONARY BYPASS CIRCUIT LEAD TO UNFAVORABLE OUTCOMES?

Musfireh Siddiqeh, Imran Khan, Ali Gohar Zamir*, Asif Mehmood Janjua*, Beenish Munir, Qudsia Anjum

Rawalpindi Institute of Cardiology Rawalpindi Pakistan, *Armed Forces Institute of Cardiology/National Institute of Heart Disease (AFIC/NIHD)/National University of Medical Sciences (NUMS) Rawalpindi Pakistan

ABSTRACT

Objective: Transfusion of residual blood left in the cardiopulmonary bypass circuit is recommended. Whether this blood should be processed or not before transfusion is not known.

Study Design: A prospective non-randomized case control study.

Place and Duration of Study: A tertiary care heart center, from Jan 2016 to Dec 2018.

Methodology: A prospective non-randomized case control study was designed. Consecutive patients operated at a tertiary care hospital were included in the study who underwent different open-heart procedures on cardiopulmonary bypass. Patients were divided into two groups. Those who received the unprocessed residual blood transfusion, residual volume retransfused at the end of cardiopulmonary bypass and those who did not, residual volume not retransfused (RVNR). Important perioperative data was collected from the hospital database and analyzed using IBM SPSS-statistics 23.0 (IBM, SPSS Inc., Chicago, IL).

Results: Of the 120 patients, 56 patients were included in the RVR group and 64 in the RVNR group. Mean age in the RVR group was 49.41 ± 14.38 years and in the RVNR group 49.27 ± 16.36 years (p=0.96). Female patients were 9 (16.07%) in the RVR group and 20 (31.25%) in the RVNR group. Residual blood left in the circuit was 271.43 ± 52 ml in the RVR group and 264.06 ± 54.5 ml in the RVNR group (p=0.45). Hemoglobin measured in ICU was 10.5 ± 1.12 gm/dl in the RVR group and 9.97 ± 1.25 gm/dl in the RVNR group (0.02). Blood products were needed in 27 patients in RVR group and 21 patients in RVNR group (p=0.57). There was no significant difference between the two groups with respect to total drainage in the first 24 hours (p=0.89). Similarly, the re-exploration rates were not different between the two groups (p=0.50).

Conclusion: Re-transfusion of residual blood left in the CPB circuit is a safe practiced. If this blood is transfused in an unprocessed form, it does not lead to adverse outcomes.

Keywords: Cardiopulmonary bypass, Residual blood re-transfusion.

INTRODUCTION

Cardiopulmonary bypass (CPB) is used for a myriad of open-heart procedures. The safety and efficacy of CPB is well established and various modifications over the years have led to safer CPB practices and better patient outcomes. These modifications include and not limited to mini CPB circuits, heparin and phosphorylcholine coated circuits, centrifugal pumps and the use of cell savers to name a few. But coagulopathy, increased use of blood products and various complications associated with blood transfusions are also known adverse effects of CPB. Various blood conservation methods have been used to mitigate these effects. Transfusion of the blood left in the CPB circuit after the patient is off bypass is practiced in almost all types of open-heart procedures performed on cardiopulmonary bypass. This residual blood can be transfused mainly in two ways; direct transfusion without processing and processing the blood in various ways before transfusion. Direct transfusion can be accomplished either by chasing it through the CPB circuit with a crystalloid solution through the arterial cannula or collecting it in a sterile infusion bag system and re-transfusing it. Various methods of processing are centrifugation, ultrafiltration and cell savers.

Transfusion of residual blood in the CPB circuit is recommended in the European Association of Cardiothoracic Surgery guidelines as
Does Auto Transfusion of Unprocessed Residual Blood Part of a Blood Management Strategy? Although this is a class I recommendation, the level of evidence is still C. There is a need for large scale randomized studies to demonstrate the safety and efficacy of this practice. Secondly, the retransfusion of unprocessed blood may increase inflammatory markers in the circulation and cause bleeding postoperatively. Data regarding its safety is sparse. We conducted this single center study to show the safety of this technique in a sizeable cohort of patients.

METHODOLOGY

A prospective comparative study was designed including all the consecutive patients undergoing open heart surgery at a tertiary care heart center from January 2016 to December 2018. Patients using coumarin derivatives or non-steroidal anti-inflammatory drugs in the immediate preoperative period were not included in the study. Patients with cardiogenic shock, use of intra-aortic balloon pump and unplanned intraoperative procedures were also excluded. Similarly, patients undergoing any type of emergency procedure, redo procedure, those with preoperative liver or kidney function derangement and any type of bleeding disorder were not included in the study. All the patients were operated using cardiopulmonary bypass. No patient received anti-fibrinolytic agent in the perioperative period. Patients were divided into two groups based upon the use of residual pump blood. Perioperative variables of interest were recorded in both the groups.

All the patients were operated using cardiopulmonary bypass using standardized techniques for preoperative preparation, anesthesia and surgery. Before commencement of cardiopulmonary bypass (CPB), full dose heparin was given according to the weight of the patient i.e. 300-400 U/Kg. The target activated coagulation time (ACT) for establishing CPB was at least 480 seconds. Additional doses of heparin were given as required to keep the ACT above 480 seconds. At the end of the procedure, the residual blood was collected in a bag and transfused slowly.

Continues variables were tested for normality with Shapiro-Wilk test and reported as mean and standard deviations. Depending upon normality, continuous variables were compared with Student t-test when continuous and Chi square test when categorical or Wilcoxon-Mann-Whitney U test. Categorical variables are reported as percentages and compared with chi square test. A p-value less than 0.05 (two tailed) was considered as significant. Statistical analysis was performed using IBM SPSS-statistics 23.0 (IBM, SPSS Inc., Chicago, IL).

RESULTS

The total number of patients included in the study was 120. The residual pump volume was returned (RVR) in 56 patients while in 64 patients, the volume was not returned (RVNR). Mean age in the RVR group was 49.41 ± 14.38 years and in the RVNR group 49.27 ± 16.36 years (p=0.96). Female patients were 9 (16.07%) in the RVR group and 20 (31.25%) in the RVNR group. Other baseline characteristics of the two groups are shown in table-I.

The mean cross clamp time and bypass times was not significantly different in the two groups (p=0.12 and p=0.06). Total protamine given in RVR group was 208.64 ± 41.3 and in the RVNR group it was 207.67 ± 45.5 (p=0.90). Activated coagulation time measured in seconds after the procedure in ICU was 132.2 ± 23.25 seconds in the RVR group and 132.3 ± 34.45 seconds in the RVNR group (p=0.98). Residual blood left in the circuit was 271.43 ± 52 ml in the RVR group and 264.06 ± 54.5 ml in the RVNR group (p=0.45). Different procedures performed in the two groups are given in table-II. The postoperative outcome variables of interest are compared in table-III. Haemoglobin measured in ICU was 10.5 ± 1.12 gm/dl in the RVR group and 9.97 ± 1.25 gm/dl in the RVNR group (p=0.02). Blood products were needed in 27 patients in RVR group and 21 patients in RVNR group (p=0.45). There was no significant difference between the two groups with respect to total drainage in the first 24 hours (p=0.89). similarly, the re-
Does Auto Transfusion of Unprocessed Residual Blood…

exploration rates were not different between the two groups ($p=0.50$). Added protamine was given after arrival in the ICU was significantly high in the RVR group. A mild to moderate correlation

| Table-I: Baseline characteristics of the groups (n=120). |
|--------------------------------------------------------|
| Parameter                                             | Residual volume returned (n=56) | Residual volume not returned (n=64) | p-value |
| Age (years)                                           | 49.41 ± 14.38                   | 49.27 ± 16.36                      | 0.96    |
| Gender                                                 | Male - 47 (83.9%)                | Female - 9 (16.07%)                | 0.05    |
|                                                        |                                      |                                      |         |
| Body surface area (Kg/m²)                              | 1.75 ± 0.17                      | 1.74 ± 0.18                        | 0.84    |
| Preoperative haemoglobin (g/dl)                        | 14.97 ± 1.3                      | 12.69 ± 1.7                        | 0.18    |
| Preoperative platelet count (×10⁹)                     | 239 ± 62                         | 236 ± 96                           | 0.82    |
| Preoperative INR                                       | 1.03 ± 0.32                      | 0.99 ± 0.21                        | 0.44    |
| Preoperative creatinine (mg/dl)                        | 1.05 ± 0.25                      | 0.92 ± 0.30                        | 0.02    |
| ACT before the procedure                               | 137.11 ± 24.8                    | 138.9 ± 29.37                      | 0.72    |

| Table-II: Intraoperative variables (n=120).            |
|--------------------------------------------------------|
| Parameter                                             | Transfusion | No transfusion | p-value |
| Cross clamp time (minutes)                            | 59.00 ± 32.12 | 47.2 ± 20.81 | 0.12    |
| CPB time                                              | 89.80 ± 43.1 | 77.27 ± 28.9 | 0.06    |
| Total protamine given at the end of CPB               | 208.64 ± 41.3 | 207.67 ± 45.5 | 0.90    |
| ACT after the procedure                                | 132.2 ± 23.25 | 132.3 ± 34.45 | 0.98    |
| Residual blood in the circuit                         | 271.43 ± 52 | 264.06 ± 54.5 | 0.45    |
| Added protamine used (mg)                              |             |               | 0.76    |
| CABG                                                  | 34          | 44            |         |
| MVR                                                   | 15          | 11            |         |
| AVR                                                   | 2           | 2             |         |
| CABG+MVR                                              | 1           | 1             |         |
| LA Myxoma                                             | 1           | 1             | NS      |
| Bentall                                               | 1           | 1             |         |
| VSR                                                   | 1           | 3             |         |
| RSOV                                                  | 0           | 1             |         |
| LV tumour                                              | 1           | 0             |         |

| Table-III: Important outcome variables.                |
|--------------------------------------------------------|
| Parameter                                             | Transfusion | No Transfusion | p-value |
| Haemoglobin in the ICU                                | 10.5 ± 1.12 | 9.97 ± 1.25 | 0.02    |
| Platelet count in ICU (×10⁹)                          | 210.5 ± 65.97 | 185.5 ± 78.87 | 0.06    |
| INR in ICU                                            | 1.11 ± 0.18 | 1.06 ± 0.20 | 0.14    |
| Packed Red cell transfusion (units)                    |             |               |         |
| 0 units                                               | 37          | 35            |         |
| 1 unit                                                | 20          | 16            |         |
| 2 units                                               | 5           | 5             | 0.57    |
| 3 units                                               | 2           | 0             |         |
| 64                                                    | 56          |               |         |
| Total drain output in the first 24 hours              | 531.6 ± 341.92 | 523.13 ± 373.01 | 0.89    |
| Re-exploration for bleeding                            | No          | 54            | 0.50    |
had transfusion of the residual blood and hemoglobin measured after arrival in the ICU.

**DISCUSSION**

This study demonstrates the safety of re-transfusion of residual unprocessed CPB circuit blood. Although non-randomized, a good number of patients were included in the study with controls that proved that residual blood, if transfused in unprocessed form, does not lead to adverse outcomes with respect to postoperative blood loss and transfusion requirements.

An important finding in our study is the avoidance of added protamine in patients with transfusion of residual blood. Daane and colleagues used added dose of protamine to offset the effects of the heparin present in the re-transfused blood. Our study showed that added protamine was required in a small quantity in both the groups and it did not differ between the groups. We used the Kaolin based activated coagulation time to decide about the additional protamine dose. Although heparinase thromboelastography (TEG) has been used for this purpose, Levin and colleagues showed in a randomized controlled trial that the use of TEG compared to ACT did not show any difference in protamine dosing.

Unprocessed blood contains inflammatory mediators and can cause activation of complement system. Many of the untoward side effects of using cardiopulmonary bypass are due to the complement release subsequent to the inflammatory reaction initiated. But as shown in our study, transfusion of residual blood did not lead to any adverse complication. Svenmarker and colleagues conducted a randomized study to investigate the cellular and inflammatory response that can be attributed to the suction blood processed with cell saver or the conventional cardiotomy suction. They concluded that cardiotomy suction blood is a cause of hemolysis and increased plasma free hemoglobin but contributes insignificantly to inflammatory response. But this should be taken with caution in our results because the mean residual blood volume was much smaller in our study compared to some of the previous studies. This might be the reason of reduced inflammatory mediator load and hence comparatively better outcome.

A significant increase in the hemoglobin level was observed in those who received the residual blood from the circuit in our study. This effect was also demonstrated by Iyer and colleagues in their cohort of 40 patients where the transfusion of unprocessed blood lead to significantly increased hemoglobin postoperatively. This improvement in hemoglobin has been attributed to the presence of a high volume of red cells in the residual pump blood. The same effect was shown by Srivanska and colleagues in their study.

Various factors can lead to coagulopathy in the immediate postoperative period. Factors like residual heparin i.e. heparin rebound, thrombolysis and platelet dysfunction etc. are all associated with coagulopathy postoperatively. Auto transfusion of the residual blood is expected to worsen the coagulation profile but this effect was not observed in our study. We demonstrated no change in the activated coagulation time done immediately after transfer to the ICU, and no change in the platelet count compared to the preoperative values. Similarly, there was a non-significant change in the values of international normalized ratio. This effect has been described previously with the use of TEG measurements by Iyer and colleagues where they demonstrated no TEG evidence of fibrinolysis or platelet dysfunction. In fact, the addition of protamine may lead to increased ACT. The resulting effect was no increase in the total drainage in the first 24 hours and the rate of re-explorations in both the groups and also no increase in blood products. 

**LIMITATION OF STUDY**

Our study has some important limitations. We did not include patients at highest risk of bleeding so our results cannot be extrapolated to these patients. The study is not randomized, although includes a sizeable number of patients. This is a single center experience and the results cannot be generalized to other centers with different perioperative protocols especially related to
the heparin and protamine dosing. Also, our study had a heterogeneity of cardiac surgical procedures which may have different pathologies which was not accounted for in our study.

**CONCLUSION**

Re-transfusion of residual blood in the CPB circuit does not lead to adverse outcomes. It can improve the hemoglobin as measured postoperatively at the cost of no increase in post-perative drainage in the first 24 hours or derangement in coagulation profile.

**CONFLICT OF INTEREST**

This study has no conflict of interest to be declared by any author.

**REFERENCES**

1. Jameel S, Colah S, Klein A. Recent advances in cardiopulmonary bypass techniques. Continuing Edu Anaesth Critical Care Pain 2010; 10(1): 20–23.
2. Sá MP, Soares EF, Santos CA. Predictors of transfusion of packed red blood cells in coronary artery bypass grafting surgery. Rev Bras Cir Cardiovasc 2011; 26(4): 552-58.
3. Muraki R, Totsugawa T, Nagata K. Cell salvage processing of residual cardiopulmonary bypass volume in minimally invasive cardiac surgery. Heart Vessels 2019; 34(1): 1280-86.
4. Authors/Task Force Members, Kunst G, Milojevic M. 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery. Br J Anaesth 2019; 123(6): 713-57.
5. Hogan M, Needham A, Ortmann E. Haemoconcentration of residual cardiopulmonary bypass blood using Hemosep: A randomised controlled trial. Anaesthesia 2015; 70(5): 563-70.
6. Walpoth BH, Eggersperger N. Effects of unprocessed and processed cardiopulmonary bypass blood retransfused into patients after cardiac surgery. Int J Artif Organs 1999; 22(1): 210.
7. Daane CR, Golab HD, Meeder JH, Wijers MJ, Bogers AJ. Processing and transfusion of residual cardiopulmonary bypass volume: effects on haemostasis, complement activation, post-operative blood loss and transfusion volume. Perfusion 2003; 18(2): 115-21.
8. Suárez CJ, Gayoso DP, Gude SF, Gómez ZJM, Rey AH, Fontanillo FMM. Method to calculate the protamine dose necessary for reversal of heparin as a function of activated clotting time in patients undergoing cardiac surgery. J Extra Corpor Technol 2013; 45(4): 235-41.
9. Levin AI, Heine AM, Coetzee JF, Coetzee A. Heparinase thromboelastography compared with activated coagulation time for protamine titration after cardiopulmonary bypass. J Cardiothoracic Vascular Anesth 2014; 28(2): 224-29.
10. Bengtsson A, Avall A, Tylman M, Bengtson JP. Effects on complement activation of a new continuous autotransfusion system. Transfus Med 1997; 7(1): 107.
11. Stahl GL, Sheman SK, Smith PK, Levy JH. Complement activation and cardiac surgery: a novel target for improving outcomes. Anesth Analg 2012; 115(4): 759-71.
12. Svenmarker S, Engström KG. The inflammatory response to recycled pericardial suction blood and the influence of cell-saving. Scand Cardiovasc J 2003; 37(3): 158-64.
13. Iyer YL, Hayward P, McNicol L, Weinberg L. The effects on coagulation of the reinfusion of unprocessed residual blood from the cardiopulmonary bypass. BMC Research Notes 2016; 9(1): 61.
14. Sirvinskas E, Lenkutis T, Raliene L, Veikutiene A, Vaskelyte J, Marchertiene I. Influence of residual blood autotransfused from cardiopulmonary bypass circuit on clinical outcome after cardiac surgery. Perfusion 2005; 20(2): 71-75.
15. Besser MW, Klein AA. The coagulopathy of cardiopulmonary bypass. Crit Rev Clin Lab Sci 2010; 47(5-6): 197-212.
16. Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998; 87(1): 781e5.
17. Scrascia G, Rotunno C, Nanna D, Rociola R, Guida P, Rubino G, et al. Pump blood processing, salvage and re-transfusion improves hemoglobin levels after coronary artery bypass grafting, but affects coagulative and fibrinolytic systems. Perfusion 2012; 27(4): 270-77.
18. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990; 76(9): 1680-97.